Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...

Insider buying surged in February. Warren Buffett continues to build a stake in a media stock, and IPOs tempted some insiders ...

President Trump’s first term was bad,” he said, “but nobody knows what’s coming. … This is truly nationalism at its worst, because he won on the campaign [largely] to protect American jobs, claiming ...

Digital health firms in the city raised $4 billion in 2024, up 60% from the previous year, according to a report released ...

TORONTO and HAIFA, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) ("NurExone” or the "Company”) is ...

Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, ...

Notably, Metsera (MTSR, NC), an emerging player in the obesity market, saw its stock soar by 47% on its first trading day. Merger and acquisition (M&A) activities in the biotech space were few but ...

Over the last year, Metsera Inc share price has been traded in a range of 3.00, hitting a high of 28.60, and a low of 25.60. Metsera Inc is listed on the CBOE trading with ticker code MTSR.US.